AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04345523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care for the treatment of COVID-19 in hospitalized patients
Study NCT01227356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib and pegylated interferon
Description: imatinib 400 mg p.o. daily pegylated interferon 50 ug s.c. weekly
Study NCT00834678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance erlotinib
Description: 150 mg po daily (days 1 - 28 of 28 day cycle)
Study NCT02876094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: dose-response
Study NCT03237078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum PS128
Description: Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
Study NCT01346969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXC 001
Description: Single-dose administered by injection four different times
Study NCT01346969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EXC 001
Description: Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1
Study NCT01346969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EXC 001
Description: Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2
Study NCT01346969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EXC 001
Description: Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
Study NCT03540030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study NCT03540030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study NCT03540030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: toradol
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study NCT03274102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Concomitant administration of EV71 vaccine with EPI vaccines
Description: 1. The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.； the recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study
Study NCT03274102 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Single injection of EPI vaccine
Description: 1. The recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study
Study NCT03540030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study NCT03540030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regional block
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study NCT03540030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study NCT03540030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV lidocaine
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study NCT03274102 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71 Vaccine only
Description: The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
Study NCT03540030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study NCT03540030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vecuronium
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study NCT03986606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSB205
Description: PSB205 is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
Study NCT03540030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study NCT03540030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desflurane
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study NCT02708862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preoxygenation
Description: After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed below, the exhaled oxygen content will be measured. All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 60 L/min for 3 min 3) Non-rebreather at 15 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
Study NCT03439787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-EPINEPHrine 0.5%-1:200,000 Injectable Solution
Description: 10 ml
Study NCT03439787 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9 %
Description: 10 ml
Study NCT04127942 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: platelet-rich plasma injection therapy of TMD
Description: The administer injected 1cc PRP in the superior temporomandibular disk joint space by ultrasound guidance.
Study NCT04127942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet-rich plasma injection therapy of TMD
Description: The administer injected 1cc PRP in the superior temporomandibular disk joint space by ultrasound guidance.
Study NCT00447005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: AG-013736 5mg twice daily \[BID\]
Study NCT04011033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNKT cells
Description: 5×10\^8-10\^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 9th, 11th week after first TAE/TACE therapy.
Study NCT04011033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human recombinated Interleukin-2
Description: IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days after iNKT cells infusion.
Study NCT04011033 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TAE/TACE
Description: TAE/TACE will be conducted to all patients at 0th week and 4th week.
Study NCT02621944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurological Outcome Assessment
Description: All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.
Study NCT04011033 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAE/TACE
Description: TAE/TACE will be conducted to all patients at 0th week and 4th week.
Study NCT01782274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes
Study NCT01782274 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
Study NCT04476147 — intervention group
Intervention type: OTHER
Intervention: Diagnostic Test: CHA2DS2-VASc, HAS-BLED and Fried Scale.
Description: This is an observational study. All the patients evaluate with CHA2DS2-VASc, HAS-BLED and Fried Scale, and observe the incidence of thrombotic events and the influence of frailty on thrombotic events in elderly patients with NVAF.
Study NCT01823341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pump suspension algorithm
Description: The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia.
Study NCT04455048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervicothoracic thrust manipulation
Description: The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. Thrust manipulation will be applied at the end of exhale.
Study NCT04455048 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cervicothoracic thrust manipulation sham
Description: The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. A soft compression will be applied at the end of exhale without a thrust.
Study NCT03307811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 22 gauge needle liver biopsy
Description: EUS will be performed. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
Study NCT04330495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hidroxicloroquina
Description: Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
Study NCT04330495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
Study NCT00842582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.
Study NCT01648933 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Rubidium PET
Description: Myocardial Perfusion Imaging
Study NCT03340779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: After obtention of a mean arterial pressure (MAP) of 65 mmHg with infusion of norepinephrine, patients with cardiogenic shock receive for 3 hours either increasing doses of norepinephrine (with a maximal MAP of 85 mmHg) or dobutamine. There is a wash-out phase of 30 minutes (decrease of norepinephrine dose or weaning of dobutamine). The third phase of the study is the administration of the comparator treatment during 3 hours. After the 6.5 hours of the study, the hemodynamic management is up to the physician.
Study NCT03340779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: After obtention of a mean arterial pressure (MAP) of 65 mmHg with infusion of norepinephrine, patients with cardiogenic shock receive for 3 hours either increasing doses of norepinephrine (with a maximal MAP of 85 mmHg) or dobutamine. There is a wash-out phase of 30 minutes (decrease of norepinephrine dose or weaning of dobutamine). The third phase of the study is the administration of the comparator treatment during 3 hours. After the 6.5 hours of the study, the hemodynamic management is up to the physician.
Study NCT00842582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.
Study NCT00842582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.
Study NCT00232479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab, docetaxel and carboplatin in dose dense regimen
Description: trastuzumab 4 mg/kg day 1 and then 2 mg/kg/week x 11, carboplatin 6 mg AUC Day 1, 15, 29, 43, docetaxel 75 mg/meter squared Days 1, 15, 29, 43, neulasta 6 mg Day 2, 16, 30, 44
Study NCT00063258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tarceva (OSI-774)
Description: 150 mg/day, starting day 1 and stopping night prior to surgery.
Study NCT00063258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Planned dose of 200 mg/m\^2 continuous IV infusion over 3 hours on Day 1 of each 21-day cycle.
Study NCT00063258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dose of AUC = 6 mg/ml × min began within 60 minutes following completion of paclitaxel infusion, infused over 15-30 minutes on Day 1 of Cycle 1 of each 21-day cycle, and then on Day 1 of each subsequent cycle according to institutional standards.
Study NCT02752386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback Training
Description: Participants will received biofeedback training to reduce arousal and pain
Study NCT02752386 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback Training
Description: Participants will received biofeedback training to reduce arousal and pain
Study NCT01717937 — intervention group
Intervention type: PROCEDURE
Intervention: Phase variance optical coherence tomography (PV-OCT)
Description: Subjects will undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images. There are no known risks associated with OCT scans.
Study NCT03498924 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measure of biomarkers in serum and endometrial tissue
Description: Blood sample and endometrial sample
Study NCT03111381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toradol
Description: IV toradol
Study NCT04570176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adrenalectomy for adrenal adenoma
Description: adrenalectomy， cystectomy and nephrectomy
Study NCT01601691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DuraSeal
Description: Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
Study NCT04310254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EDTA and CHX Solution
Description: The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with Qmix 2in1 solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
Study NCT04310254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EDTA Solution
Description: The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with EDTA solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
Study NCT04122534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Somatic Mindfulness Training
Description: Educational and experiential training to reduce occupational-based secondary trauma.
Study NCT04310254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CHX Solution
Description: The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with CHX solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
Study NCT00402025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Talimogene laherparepvec administered by direct injection into pancreatic tumors using EUS-guided FNI, up to a maximum of 4 mL per treatment.
Study NCT01770002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Everted suture technique
Study NCT01770002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-everted suture technique
Study NCT03237117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Description: to evaluate the effect of GH administration in the donated oocyte recipient program among women with RIF (repeated implantation failure)
Study NCT03237117 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone (GH)
Description: to evaluate the effect of GH administration in the donated oocyte recipient program among women with RIF (repeated implantation failure)
Study NCT03699033 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 2.5 Gy/fraction
Description: Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined with Carboplatin and Paclitaxel
Study NCT03699033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation.
Study NCT03699033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation.
Study NCT03858023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: The hippotherapy program consists of 2 sessions per week for 15 weeks. One session is 30-minute session. The program involves 2 therapists and 3 personnel for safety issues.
Study NCT03380416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Portfolio Diet
Description: Medium-term (8 weeks ) nutritional intervention
Study NCT03380416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MUFA Diet
Description: Medium-term (8 weeks ) nutritional intervention used as control
Study NCT01632163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form:solution~Route of administration: subcutaneous injection
Study NCT01632163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:solution~Route of administration: subcutaneous injection
Study NCT03186716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colostrum
Description: Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
Study NCT03186716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
Study NCT04481841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oryzanol + vitamin B2 (riboflavin) + vitamin E
Description: 1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.~2.Therapeutic regimen of experimental group On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment.